{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:51:48Z","timestamp":1790707908445,"version":"4.1.0"},"reference-count":59,"publisher":"Portland Press Ltd.","issue":"4","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,8,1]]},"abstract":"<jats:p>The aim of the present study was to evaluate the effects of ST (rosuvastatin) and GZ (rosiglitazone) on IR (insulin resistance) and on liver as well as adipose tissue in mice fed on an HF (high-fat) diet. Our data show that treatment with ST resulted in a marked improvement in insulin sensitivity characterized by enhanced glucose clearance during the insulin tolerance test and a 70% decrease in the HOMA-IR (homoeostasis model assessment of insulin resistance) index level (P=0.0008). The ST-treated mice exhibited lower gains in BM (body mass; \u22128%; P&amp;lt;0.01) and visceral fat pad thickness (\u221260%; P&amp;lt;0.01) compared with the untreated HF group. In comparison with HF-diet-fed mice, HF+ST-treated mice showed a significant reduction in hepatomegaly and liver steatosis (\u22126%, P&amp;lt;0.05; and \u221221%, P&amp;lt;0.01 respectively). In HF+ST-treated mice, the hepatic TAG (triacylglycerol) levels were reduced by 58% compared with the HF group (P&amp;lt;0.01). In addition, the expression of SREBP-1c (sterol-regulatory-element-binding protein-1c) was decreased by 50% in the livers of HF+ST-treated mice (P&amp;lt;0.01) relative to the HF-diet-fed mice. The levels of resistin were lower in the HF+ST-treated group compared with the HF group (44% less, P&amp;lt; 0.01). In conclusion, we demonstrated that ST treatment improved insulin sensitivity and decreased liver steatosis in mice fed on an HF diet. Furthermore, ST reduced BM gains, improved the circulating levels of plasma cholesterol and TAG, and reduced hepatic TAG, which was concomitant with lower resistin levels.<\/jats:p>","DOI":"10.1042\/cs20110373","type":"journal-article","created":{"date-parts":[[2012,3,16]],"date-time":"2012-03-16T09:16:11Z","timestamp":1331889371000},"page":"259-270","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet"],"prefix":"10.1042","volume":"123","author":[{"given":"Julio\u00a0Cesar","family":"Fraulob","sequence":"first","affiliation":[{"name":"Laboratory of Morphometry, Metabolism and Cardiovascular Disease, Biomedical Centre, State University of Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Souza-Mello","sequence":"additional","affiliation":[{"name":"Laboratory of Morphometry, Metabolism and Cardiovascular Disease, Biomedical Centre, State University of Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia\u00a0Barbosa","family":"Aguila","sequence":"additional","affiliation":[{"name":"Laboratory of Morphometry, Metabolism and Cardiovascular Disease, Biomedical Centre, State University of Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos\u00a0Alberto","family":"Mandarim-de-Lacerda","sequence":"additional","affiliation":[{"name":"Laboratory of Morphometry, Metabolism and Cardiovascular Disease, Biomedical Centre, State University of Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2012,4,30]]},"reference":[{"key":"2021113010260532800_B1","first-page":"1","article-title":"Hepatic insulin resistance and nonalcoholic fatty liver disease","volume-title":"Insulin Resistance: Symptoms, Causes and Treatment","author":"Aguila","year":"2010"},{"key":"2021113010260532800_B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mito.2005.10.004","article-title":"Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it","volume":"6","author":"Begriche","year":"2006","journal-title":"Mitochondrion"},{"key":"2021113010260532800_B3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00535-010-0340-3","article-title":"The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease","volume":"46","author":"Eguchi","year":"2011","journal-title":"J. Gastroenterol."},{"key":"2021113010260532800_B4","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2021113010260532800_B5","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1136\/gut.2011.242016","article-title":"Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease","volume":"60","author":"Wong","year":"2011","journal-title":"Gut"},{"key":"2021113010260532800_B6","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1440-1746.2009.06086.x","article-title":"Endoplasmic reticulum stress involved in the course of lipogenesis in fatty acids-induced hepatic steatosis","volume":"25","author":"Liu","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"key":"2021113010260532800_B7","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1742-4658.2008.06806.x","article-title":"SREBPs: physiology and pathophysiology of the SREBP family","volume":"276","author":"Shimano","year":"2009","journal-title":"FEBS J."},{"key":"2021113010260532800_B8","first-page":"507","article-title":"SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease","volume":"21","author":"Kohjima","year":"2008","journal-title":"Int. J. Mol. Med."},{"key":"2021113010260532800_B9","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1590\/S0100-879X2010007500030","article-title":"Beneficial effects of exercise training (treadmill) on insulin resistance and nonalcoholic fatty liver disease in high-fat fed C57BL\/6 mice","volume":"43","author":"Marques","year":"2010","journal-title":"Braz. J. Med. Biol. Res."},{"key":"2021113010260532800_B10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"2021113010260532800_B11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1042\/CS20100061","article-title":"Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL\/6 mice fed on a very high-fat diet","volume":"119","author":"Souza-Mello","year":"2010","journal-title":"Clin. Sci."},{"key":"2021113010260532800_B12","doi-asserted-by":"crossref","first-page":"650","DOI":"10.7326\/0003-4819-140-8-200404200-00013","article-title":"Pharmacologic lipid-lowering therapy in type\u00a02 diabetes mellitus: background paper for the American College of Physicians","volume":"140","author":"Vijan","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"2021113010260532800_B13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1210\/jc.2005-2084","article-title":"Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia","volume":"91","author":"Ginsberg","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021113010260532800_B14","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(06)69292-1","article-title":"Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the treating to new targets study","volume":"368","author":"Deedwania","year":"2006","journal-title":"Lancet"},{"key":"2021113010260532800_B15","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.atherosclerosis.2007.11.003","article-title":"Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization","volume":"198","author":"Naples","year":"2008","journal-title":"Atherosclerosis"},{"key":"2021113010260532800_B16","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.clinthera.2010.03.018","article-title":"Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study","volume":"32","author":"Rizos","year":"2010","journal-title":"Clin. Ther."},{"key":"2021113010260532800_B17","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.1152\/ajpendo.00157.2010","article-title":"The many facets of PPAR\u03b3: novel insights for the skeleton","volume":"299","author":"Kawai","year":"2010","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"2021113010260532800_B18","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.2337\/diabetes.54.8.2460","article-title":"Therapeutic roles of peroxisome proliferator-activated receptor agonists","volume":"54","author":"Staels","year":"2005","journal-title":"Diabetes"},{"key":"2021113010260532800_B19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jhep.2007.10.004","article-title":"Rosiglitazone: possible complications and treatment of non-alcoholic steatohepatitis (NASH)","volume":"48","author":"Henriksen","year":"2008","journal-title":"J. Hepatol."},{"key":"2021113010260532800_B20","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/hep.21687","article-title":"Effects of rosiglitazone on the liver histology and mitochondrial function in ob\/ob mice","volume":"46","author":"Garcia-Ruiz","year":"2007","journal-title":"Hepatology"},{"key":"2021113010260532800_B21","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.2337\/diabetes.54.6.1854","article-title":"Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of type\u00a02 diabetes","volume":"54","author":"Pan","year":"2005","journal-title":"Diabetes"},{"key":"2021113010260532800_B22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.vph.2005.11.011","article-title":"Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type\u00a02 diabetes: relation to dysregulated phosphatidylcholine metabolism","volume":"45","author":"Pan","year":"2006","journal-title":"Vascul. Pharmacol."},{"key":"2021113010260532800_B23","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"2021113010260532800_B24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijcard.2009.01.064","article-title":"Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials","volume":"143","author":"Mannucci","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"2021113010260532800_B25","doi-asserted-by":"crossref","first-page":"c5291","DOI":"10.1136\/bmj.c5291","article-title":"European regulatory body recommends suspension of rosiglitazone","volume":"341","author":"Cohen","year":"2010","journal-title":"BMJ"},{"key":"2021113010260532800_B26","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3164\/jcbn.09-83","article-title":"A mouse model of metabolic syndrome: insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in C57BL\/6 mice fed a high fat diet","volume":"46","author":"Fraulob","year":"2010","journal-title":"J. Clin. Biochem. Nutr."},{"key":"2021113010260532800_B27","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/jn\/123.11.1939","article-title":"AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet","volume":"123","author":"Reeves","year":"1993","journal-title":"J. Nutr."},{"key":"2021113010260532800_B28","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"2021113010260532800_B29","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1034\/j.1478-3231.2003.00858.x","article-title":"Dietary effect of different high-fat diet on rat liver stereology","volume":"23","author":"Aguila","year":"2003","journal-title":"Liver Int."},{"key":"2021113010260532800_B30","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cyto.2009.03.006","article-title":"Effects of diet and exercise on metabolic disturbances in high-fat diet-fed mice","volume":"46","author":"Vieira","year":"2009","journal-title":"Cytokine"},{"key":"2021113010260532800_B31","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"},{"key":"2021113010260532800_B32","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.2337\/diabetes.54.11.3140","article-title":"Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study","volume":"54","author":"Hanley","year":"2005","journal-title":"Diabetes"},{"key":"2021113010260532800_B33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11894-008-0012-0","article-title":"Nonalcoholic fatty liver disease as a component of the metabolic syndrome","volume":"10","author":"Khashab","year":"2008","journal-title":"Curr. Gastroenterol. Rep."},{"key":"2021113010260532800_B34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.metabol.2007.07.021","article-title":"Statin modulates insulin signaling and insulin resistance in liver and muscle of rats fed a high-fat diet","volume":"57","author":"Lalli","year":"2008","journal-title":"Metab., Clin. Exp."},{"key":"2021113010260532800_B35","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jacl.2011.06.013","article-title":"3-Hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy","volume":"5","author":"Tzefos","year":"2011","journal-title":"J. Clin. Lipidol."},{"key":"2021113010260532800_B36","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1042\/CS20050078","article-title":"Role of resistin in obesity, insulin resistance and Type\u00a0II diabetes","volume":"109","author":"Kusminski","year":"2005","journal-title":"Clin. Sci."},{"key":"2021113010260532800_B37","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/0014-5793(95)00719-P","article-title":"Effects of fasting and refeeding on ob gene expression in white adipose tissue of lean and obese (ob\/ob) mice","volume":"368","author":"Trayhurn","year":"1995","journal-title":"FEBS Lett."},{"key":"2021113010260532800_B38","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/jhep.2002.34738","article-title":"Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?","volume":"36","author":"Chitturi","year":"2002","journal-title":"Hepatology"},{"key":"2021113010260532800_B39","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.numecd.2008.12.015","article-title":"Hepatic lipid metabolism and non-alcoholic fatty liver disease","volume":"19","author":"Tessari","year":"2009","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"2021113010260532800_B40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2004.12.003","article-title":"AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism","volume":"1","author":"Kahn","year":"2005","journal-title":"Cell Metab."},{"key":"2021113010260532800_B41","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/415339a","article-title":"Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase","volume":"415","author":"Minokoshi","year":"2002","journal-title":"Nature"},{"key":"2021113010260532800_B42","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1096\/fj.00-0590","article-title":"Diseases of liporegulation: new perspective on obesity and related disorders","volume":"15","author":"Unger","year":"2001","journal-title":"FASEB J."},{"key":"2021113010260532800_B43","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.2337\/db06-S018","article-title":"Brain adipocytokine action and metabolic regulation","volume":"55","author":"Ahima","year":"2006","journal-title":"Diabetes"},{"key":"2021113010260532800_B44","doi-asserted-by":"crossref","first-page":"35832","DOI":"10.1074\/jbc.274.50.35832","article-title":"Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes","volume":"274","author":"Shimano","year":"1999","journal-title":"J. Biol. Chem."},{"key":"2021113010260532800_B45","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2337\/diabetes.53.3.560","article-title":"Insulin-independent induction of sterol regulatory element-binding protein-1c expression in the livers of streptozotocin-treated mice","volume":"53","author":"Matsuzaka","year":"2004","journal-title":"Diabetes"},{"key":"2021113010260532800_B46","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2337\/diabetes.54.2.492","article-title":"Transgenic mice overexpressing nuclear SREBP-1c in pancreatic \u03b2-cells","volume":"54","author":"Takahashi","year":"2005","journal-title":"Diabetes"},{"key":"2021113010260532800_B47","doi-asserted-by":"crossref","first-page":"19353","DOI":"10.1074\/jbc.M201584200","article-title":"Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)\/Lep(ob) mice","volume":"277","author":"Yahagi","year":"2002","journal-title":"J. Biol. Chem."},{"key":"2021113010260532800_B48","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.2337\/db06-1806","article-title":"Palmitate impairs and eicosapentaenoate restores insulin secretion through regulation of SREBP-1c in pancreatic islets","volume":"57","author":"Kato","year":"2008","journal-title":"Diabetes"},{"key":"2021113010260532800_B49","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cell.2004.11.043","article-title":"Hyperlipidemic effects of dietary saturated fats mediated through PGC-1\u03b2 coactivation of SREBP","volume":"120","author":"Lin","year":"2005","journal-title":"Cell"},{"key":"2021113010260532800_B50","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/ncb1111","article-title":"SREBPs suppress IRS-2-mediated insulin signalling in the liver","volume":"6","author":"Ide","year":"2004","journal-title":"Nat. Cell Biol."},{"key":"2021113010260532800_B51","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/10409231003667500","article-title":"Genetic control of de novo lipogenesis: role in diet-induced obesity","volume":"45","author":"Strable","year":"2010","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"2021113010260532800_B52","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.freeradbiomed.2009.07.016","article-title":"SREBP-1c in nonalcoholic fatty liver disease induced by Western-type high-fat diet plus fructose in rats","volume":"47","author":"Aragno","year":"2009","journal-title":"Free Radical Biol. Med."},{"key":"2021113010260532800_B53","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S1386-6346(01)00172-3","article-title":"Enhanced GLUT2 gene expression in an oleic acid-induced in vitro fatty liver model","volume":"23","author":"Okamoto","year":"2002","journal-title":"Hepatol. Res."},{"key":"2021113010260532800_B54","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2337\/diabetes.54.6.1684","article-title":"Glucose-stimulated upregulation of GLUT2 gene is mediated by sterol response element-binding protein-1c in the hepatocytes","volume":"54","author":"Im","year":"2005","journal-title":"Diabetes"},{"key":"2021113010260532800_B55","first-page":"1080","article-title":"Enhancement in liver SREBP-1c\/PPAR-\u03b1 ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochim","volume":"1792","author":"Pettinelli","year":"2009","journal-title":"Biophys. Acta"},{"key":"2021113010260532800_B56","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0005-2760(96)00066-5","article-title":"The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation","volume":"1302","author":"Schoonjans","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"2021113010260532800_B57","first-page":"351","article-title":"Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease","volume":"20","author":"Kohjima","year":"2007","journal-title":"Int. J. Mol. Med."},{"key":"2021113010260532800_B58","first-page":"631","article-title":"Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease","volume":"16","author":"Nakamuta","year":"2005","journal-title":"Int. J. Mol. Med."},{"key":"2021113010260532800_B59","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00005344-200501000-00010","article-title":"Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-leiden mice","volume":"45","author":"Delsing","year":"2005","journal-title":"J. Cardiovasc. Pharmacol."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/123\/4\/259\/441935\/cs1230259.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/123\/4\/259\/441935\/cs1230259.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T10:59:52Z","timestamp":1638269992000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/123\/4\/259\/69090\/Beneficial-effects-of-rosuvastatin-on-insulin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,30]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20110373","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,30]]}}}